Search
Semaglutide Treatment Options for Type 2 Diabetes
A collection of 95 research studies in Type 2 Diabetes where Semaglutide is the interventional treatment. Semaglutide is used for conditions such as Type 2 Diabetes.
13 - 24 of 95
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Type 2 Diabetes
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Diabetic Peripheral Neuropathy Clinical Study (Raleigh)
Recruiting
If you struggle with chronic nerve pain in your legs due to diabetes (diabetic peripheral neuropathy, or DPN), Vertex Pharmaceuticals is conducting research studies that may be an option.
Conditions:
Diabetic Peripheral Neuropathy
Diabetes
Type 2 Diabetes
Featured Trial
Diabetic Peripheral Neuropathy Clinical Study
Recruiting
If you struggle with chronic nerve pain in your legs due to diabetes (diabetic peripheral neuropathy, or DPN), Vertex Pharmaceuticals is conducting research studies that may be an option.
Conditions:
Diabetes
Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus
Type 1
Semaglutide in CFRD
Completed
This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Pharmacogenetics of Response to GLP1R Agonists
Recruiting
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims:
1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated fir... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
06/26/2025
Locations: Amish Research Clinic, Lancaster, Pennsylvania
Conditions: Obesity, Diabetes Type 2
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
Active Not Recruiting
This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. The purpose of the study is to see how well RYBELSUS® is at lowering blood sugar compared to other tablets when used in addition to metformin. Participants doctor will give participants either RYBELSUS® or any other blood sugar lowering tablets - which treatment participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: FDRC, Costa Mesa, California +21 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
Active Not Recruiting
This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine. The study will also test if semaglutide is safe in children and teenagers. Participants will either get semaglutide or the dummy medicine - which one is decided by chance. Participants will take 1 tablet of the study medicine every morning on an empty stomach. They have to wait 30 minutes before they ea... Read More
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
06/17/2025
Locations: Children's Hospital Los Angeles - Endocrinology, Los Angeles, California +65 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
Completed
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.
Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance.
Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes.
Participants will get the study medicine in a pen. Participan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Academic Medical Research Institute, Los Angeles, California +30 locations
Conditions: Diabetes Mellitus, Type 2, Chronic Kidney Disease
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Completed
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home vi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: San Fernando Valley Hlth Inst, LLC, Canoga Park, California +111 locations
Conditions: Diabetes Mellitus, Type 2, Obesity
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Active Not Recruiting
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Del Sol Research Management, LLC, Tucson, Arizona +180 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Active Not Recruiting
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participant will get either CagriSema or "dummy" medicine and which treatment they get is decided by chance. Participant will take the study medicine together with their current diabetes medi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Valley Clinical Trials, Inc., Northridge, California +48 locations
Conditions: Type 2 Diabetes
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Recruiting
The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Diabetic Kidney Disease, Type 1 Diabetes
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
Recruiting
This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way.... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
05/30/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +1 locations
Conditions: Diabetes Mellitus, Type 1
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Active Not Recruiting
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Nat Res Inst Huntington Park, Huntington Park, California +48 locations
Conditions: Type 2 Diabetes
ADJUnct Semaglutide Treatment in Type 1 Diabetes
Completed
The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/29/2025
Locations: Barbara Davis Center for Diabetes, Aurora, Colorado +3 locations
Conditions: Type 1 Diabetes, Obesity
13 - 24 of 95